Genentech Inc. has disclosed 2,8-diazaspiro [4.5] decane compounds acting as serine/threonine-protein kinase LATS1 and/or LATS2 inhibitors reported to be useful for the treatment of acute respiratory distress syndrome (ARDS).
Rewind Therapeutics NV has described 3-pyrrolylsulfonamide compounds acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists reported to be useful for diagnosis and treatment of neurodegeneration, leukodystrophies, optic neuropathy, Charcot-Marie-Tooth disease, demyelinating, psychiatric and genetic disorders, among others.
Asieris Pharmaceuticals Co. Ltd. has divulged 7-nitro-8-hydroxyquinoline derivatives reported to be useful for the treatment of urinary tract infections, and bladder and prostate cancer.
Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. have identified substituted phenyl-1H-pyrrolo [2, 3-c] pyridine derivatives acting as menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.
Janssen R&D (Ireland) and Johnson & Johnson (China) Investment Ltd. have disclosed fused heterocyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections.
Impact Therapeutics (Shanghai) Inc. has synthesized nitrogen-containing fused heteroaromatic bicyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. researchers have developed prodrugs acting as apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, particularly chronic myeloid leukemia.
Research at Azcuris Co. Ltd. has led to the development of thymic stromal lymphopoietin (TSLP)/cytokine receptor-like factor 2 (CRLF2; TSLPR) interaction inhibitors, which are reported to be useful for the treatment of autoimmune diseases, chronic obstructive pulmonary disease (COPD), allergy, asthma, allergic rhinitis and chronic rhinosinusitis.
Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors, reported to be potentially useful for the treatment of cancer, have been detailed in a patent from Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
RSS
